title: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis.
abstract: Epidermal growth factor receptor (EGFR) immunoreactivity was evaluated in 85 cases of invasive transitional cell carcinoma of the bladder. The impact of EGFR staining on patient survival was compared with tumor stage, histologic grade, immunoreactivity for c-erb B-2 and proliferating cell nuclear antigen, flow cytometrically determined S-phase fraction and DNA ploidy, abnormal expression of blood-group-related antigens, and patient blood type. Using a new monoclonal anti-EGFR antibody reactive in formalin-fixed tissue, the authors found a significant correlation between EGFR expression and high tumor stage, and between EGFR expression and poor patient outcome. However, EGFR expression as a predictor of prognosis was not independent of stage. An intriguing association between patient blood type and patient survival was noted. Other indices did not predict patient outcome after data were adjusted for stage.
authors.affiliation: Department of Laboratory Medicine and Pathology, School of Public Health, University of Minnesota, Minneapolis.
authors.forename: P L
authors.initials: PL
authors.lastname: Nguyen
authors.forename: P E
authors.initials: PE
authors.lastname: Swanson
authors.forename: W
authors.initials: W
authors.lastname: Jaszcz
authors.forename: D M
authors.initials: DM
authors.lastname: Aeppli
authors.forename: G
authors.initials: G
authors.lastname: Zhang
authors.forename: T P
authors.initials: TP
authors.lastname: Singleton
authors.forename: S
authors.initials: S
authors.lastname: Ward
authors.forename: D
authors.initials: D
authors.lastname: Dykoski
authors.forename: J
authors.initials: J
authors.lastname: Harvey
authors.forename: G A
authors.initials: GA
authors.lastname: Niehans
mesh_terms: D000017:ABO Blood-Group System / Q000032:analysis; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000453:epidemiology* / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D066246:ErbB Receptors / Q000032:analysis* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007519:Isoantigens / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000032:analysis; D011003:Ploidies; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen; D011518:Proto-Oncogene Proteins / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases; D016196:S Phase; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000453:epidemiology* / Q000648:ultrastructure
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D004273:DNA, Neoplasm; D066246:ErbB Receptors; D007519:Isoantigens; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases